Therapeutic banner
Therapeutic banner

Transthyretin (ATTR) Amyloidosis

View the latest scientific data presented at congress events in the past 2 years and discover peer-reviewed publications related to ATTR Amyloidosis.
The information on this page pertains to select congress and publication resources. It is not intended to serve as a comprehensive list of all congress and publications resources.

Explore Therapeutic Areas

Publications

View More Arrow

Transthyretin Amyloidosis (ATTR)

Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy

JAMA Neurology

Author(s)

David Adams, Jonas Wixner, Michael Polydefkis, et al

January 2025

Transthyretin Amyloidosis (ATTR)

The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement

Orphanet Journal of Rare Diseases

Author(s)

Chafic Karam, Colleen Moffit, Catherine Summers, et al

November 2024

Transthyretin Amyloidosis (ATTR)

Outpatient Worsening Heart Failure in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial

Journal of the American College of Cardiology

Author(s)

Marianna Fontana, Mathew S. Maurer, Julian D. Gillmore, et al

November 2024

Transthyretin Amyloidosis (ATTR)

Neurofilament light chain as a biomarker for hereditary ATTR amyloidosis

Amyloid

Author(s)

Masateru Tajiri, Mitsuto Sato, Minori Kodaira, et al

October 2024

Transthyretin Amyloidosis (ATTR)

Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

New England Journal of Medicine

Author(s)

Marianna Fontana, John L. Berk, Julian D. Gillmore, et al

August 2024

Transthyretin Amyloidosis (ATTR)

Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy

European Journal of Neurology

Author(s)

Celine Labeyrie, Madeline Merkel, Sakshi Sethi, et al

July 2024